MARKET

LHDX

LHDX

Lucira Health, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.710
+0.095
+5.88%
After Hours: 1.680 -0.03 -1.75% 18:12 06/24 EDT
OPEN
1.690
PREV CLOSE
1.615
HIGH
1.900
LOW
1.660
VOLUME
59.71K
TURNOVER
0
52 WEEK HIGH
11.10
52 WEEK LOW
1.360
MARKET CAP
68.17M
P/E (TTM)
-1.6770
1D
5D
1M
3M
1Y
5Y
73 Biggest Movers From Yesterday
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.
Benzinga · 05/17 08:49
XERS, AGRX and LHDX among mid-day movers
Gainers: Data Storage Corporation (DTST) +40%. Indonesia Energy Corporation (INDO) +30%. Harpoon Therapeutics (HARP) +28%. Pulse Biosciences (PLSE) +24%. Praxis Precision Medicines (PRAX) +24%. Xeris Biopharma Holdings (XERS) +24%. Griffon
Seekingalpha · 05/16 16:31
41 Stocks Moving In Monday's Mid-Day Session
Gainers Data Storage Corporation (NASDAQ: DTST) shares jumped 51.1% to $3.4750 after the company reported better-than-expected Q1 financial results.
Benzinga · 05/16 16:10
Lucira Health: Q1 Earnings Insights
Lucira Health (NASDAQ:LHDX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Lucira Health beat estimated earnings by 600.0%, reporting an EPS of $0.4 versus an esti...
Benzinga · 05/12 21:36
BRIEF-Lucira Health Reports Qtrly EPS $0.31
reuters.com · 05/12 21:24
BRIEF-Lucira Health Reports Q1 Revenue Of $90.5 Million
reuters.com · 05/12 21:00
Lucira Health GAAP EPS of $0.31 beats by $0.22, revenue of $90.5M beats by $4.15M
Lucira Health press release (NASDAQ:LHDX): Q1 GAAP EPS of $0.31 beats by $0.22. Revenue of $90.5M (vs. $4.5M last year) beats by $4.15M. Revenue growth was driven by COVID-19 test
Seekingalpha · 05/12 20:57
Lucira Health Q1 Adj. Net Income $16.668M vs Loss $13.599M In Same Qtr. Last Year, Sales $90.50M Beat $85.35M Estimate
Lucira Health (NASDAQ:LHDX) reported quarterly sales of $90.50 million which beat the analyst consensus estimate of $85.35 million by 6.03 percent. This is a 1.90K percent increase over sales of $4.52 million the same
Benzinga · 05/12 20:04
More
No Data
Learn about the latest financial forecast of LHDX. Analyze the recent business situations of Lucira Health, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
33.33%Buy
33.33%Hold
33.33%Under-perform
0.00%Sell
Analyst Price Target
The average LHDX stock price target is 3.500 with a high estimate of 4.000 and a low estimate of 3.000.
High4.000
Average3.500
Low3.000
Current 1.710
EPS
Actual
Estimate
-0.34-0.130.080.29
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 41
Institutional Holdings: 23.74M
% Owned: 59.54%
Shares Outstanding: 39.87M
TypeInstitutionsShares
Increased
12
402.58K
New
4
31.78K
Decreased
14
1.02M
Sold Out
9
255.67K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.57%
Healthcare Equipment & Supplies
+2.14%
Key Executives
President/Chief Executive Officer/Director
Erik Engelson
Chief Financial Officer/Treasurer
Daniel George
Chief Operating Officer
Hansgregory Hartmann
Executive Vice President
Ghazi Kashmolah
Executive Vice President
Kelly Lewis Brezoczky
Chief Technology Officer
Debkishore Mitra
Vice President - Operations
Tamanna Prashar
Independent Director
Sandra Gardiner
Independent Director
David Lamond
Independent Director
Erica Rogers
Independent Director
Lior Susan
Independent Director
Steve Tablak
Independent Director
Tuff Yen
No Data
No Data
About LHDX
Lucira Health, Inc. is medical technology company. The Company is focused on the development and commercialization of transformative and infectious disease test kits. The Company has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and test kit that is powered by two AA batteries and fit in the palm of a hand. Its initial focus is within respiratory diseases, starting with COVID-19 and influenza A and B virus indications. It has developed LUCIRA COVID-19 All-In-One Test Kit (COVID-19 test kit), is a single-use, molecular in vitro diagnostic test that has an analytical sensitivity to detect the SARS-CoV-2 virus. The test is authorized for prescription at-home use.

Webull offers kinds of Lucira Health Inc stock information, including NASDAQ:LHDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LHDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LHDX stock methods without spending real money on the virtual paper trading platform.